MedChemComm : Impact Factor & More
eISSN: 2040-2511pISSN: 2040-2503
Share this on:
Key Metrics
CiteScore 
2.24
H-Index
44
SNIP
0.72
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on MedChemComm
MedChemComm Journal Specifications
Indexed in the following public directories
CrossRef 
SJR 
Scopus
| Overview | |
| Publisher | Royal Society of Chemistry |
Planning to publish in MedChemComm ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in MedChemComm
Ruthenium(ii) polypyridyl complexes and the DNA damage response: mechanisms and therapeutic implications.
- 6 May 2026
- RSC medicinal chemistry
Small-molecule therapeutics for diabetic retinopathy: from VEGFR inhibitors to emerging non-VEGF targets.
- 1 May 2026
- RSC medicinal chemistry
Development of novel chalcone-based quinazoline derivatives as dual VEGFR-2 and EGFR inhibitors.
- 1 May 2026
- RSC medicinal chemistry
Histone deacetylase-based dual inhibitors: research progress focusing on non-small cell lung cancer therapy.
- 29 Apr 2026
- RSC medicinal chemistry
Structure-guided optimisation of fenofibrate-derived oxidative phosphorylation inhibitors to modify tumour hypoxia.
- 28 Apr 2026
- RSC medicinal chemistry
Beyond acrylamide: a structure-guided investigation of covalent warheads in the development of CDK7 inhibitors.
- 10 Apr 2026
- RSC medicinal chemistry
Ruthenium(ii) polypyridyl complexes and the DNA damage response: mechanisms and therapeutic implications.
- 6 May 2026
- RSC medicinal chemistry
Small-molecule therapeutics for diabetic retinopathy: from VEGFR inhibitors to emerging non-VEGF targets.
- 1 May 2026
- RSC medicinal chemistry
Development of novel chalcone-based quinazoline derivatives as dual VEGFR-2 and EGFR inhibitors.
- 1 May 2026
- RSC medicinal chemistry
Histone deacetylase-based dual inhibitors: research progress focusing on non-small cell lung cancer therapy.
- 29 Apr 2026
- RSC medicinal chemistry
Structure-guided optimisation of fenofibrate-derived oxidative phosphorylation inhibitors to modify tumour hypoxia.
- 28 Apr 2026
- RSC medicinal chemistry
Beyond acrylamide: a structure-guided investigation of covalent warheads in the development of CDK7 inhibitors.
- 10 Apr 2026
- RSC medicinal chemistry
FAQs on MedChemComm
How many articles did MedChemComm publish last year? 
What is the eISSN & pISSN for MedChemComm?
What is Citescore for MedChemComm?
What is the H Index for MedChemComm ?
What is SNIP score for MedChemComm?
Who is the publisher of MedChemComm?
